US FDA wants more data on once-monthly Invega
This article was originally published in Scrip
The US FDAhas asked Johnson & Johnsonin a complete response letter to provide additional information on paliperidone palmitate, its investigational once-monthly formulation of Invega (paliperidone), for treating schizophrenia and preventing recurrence of symptoms.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.